Go to:
Logótipo
Você está em: Start > MI134263

Therapeutic Targets in Vascular Diseases

Code: MI134263     Acronym: ATDV

Keywords
Classification Keyword
OFICIAL Health Sciences

Instance: 2013/2014 - 2S Ícone do Moodle

Active? Yes
Responsible unit: Pharmacology Laboratory
Course/CS Responsible: MSc in Pharmaceutical Sciences

Cycles of Study/Courses

Acronym No. of Students Study Plan Curricular Years Credits UCN Credits ECTS Contact hours Total Time
MICF 26 Official Curriculum 4 - 4 52 108

Teaching language

Portuguese

Objectives

Within the course of Therapeutic Targets in Vascular Disease it is intended that the student understand concepts and issues related to the mechanisms involved in the development of vasculopathies as well as with the available experimental approaches. In conjunction with the laboratory component will be crafted communication skills among students (debates and discussions of papers); still be worked management skills and teamwork through the conceptualization of a scientific project so to promote the initiative, leadership and management, the scientific project aims to integrate the concepts presented in the theoretical with the experimental methodologies, answering questions and debating issues, reasoning and stimulated interest in this area of ​​knowledge.

Learning outcomes and competences

It is intended that learning matches a responsible autonomy of the student through the reading and discussion of scientific articles (original and revised) related to this area of knowledge taking as a starting point weekly theme, and it promotes the application of concepts designed to develop skills related to the classical and emerging mechanisms in pharmacology / pharmacotherapy of various vascular disorders. It is also intended that students develop personal and interpersonal skills such as communication between students, management skills and teamwork; promotion initiative, leadership and management

Working method

Presencial

Program


theoretical program

1) The structure of the vascular wall (artery and vein) cells and vascular wall structure; vascular remodeling.

2) Regulation of vascular tone: biomechanics and vascular regulation of vascular tone. Humoral regulation of vascular tone and ion. Neurogenic regulation of vascular tone.

3) Mechanisms of vascular damage and regeneration as emerging therapeutic targets: endothelial dysfunction and vascular disease, vascular aging, oxidative stress and vascular inflammation, biomarkers for vascular risk.

4) Classic and emerging therapeutic targets in the treatment of vascular diseases:

a) Vascular disorders and hypertensive, diabetic and atherosclerotic.

b) Changes in specific vascular beds: coronary, carotid, renal, mesenteric, intermittent claudication, training and development of aneurysms, vascular changes in erectile dysfunction, venous thromboembolic disease, pulmonary embolism, varicose veins and vascular ulcers of the lower extremities; arterial ischemia of the extremities lower.

  laboratory program

1) Strategies searching: sources of information and communication technologies; quality assessment of different types of literature; quality of information published.

2) Development of concept maps as an aid in the study of models / methodologies in the investigation of vascular disease: analysis, critique and discussion of scientific papers and articles on the themes emerging in the area.

3) Preparation of a project for testing therapeutic targets in vascular disease: selection of the topics; stages in project design, presentation and discussion of the project.


Mandatory literature

Luis M. Botana, Mabel Loza; Therapeutic Targets: Modulation, Inhibition, and Activation. ISBN: 978-04-7058-719-5

Complementary Bibliography

Maffei, Francisco H. de A.- Lastória, Sidnei-Yoshida, Winston B. - Rollo, Hamilton A.- Giannini, Mariangela- Moura, Regina; Doenças Vasculares Periféricas. ISBN: 978-85-2771-460-0

Teaching methods and learning activities

The teaching of the course of Therapeutic Targets in Vascular Disease intended to be a teaching hybrid (B-learning) mostly but complemented with classroom teaching tutorial using an e-learning platform. The program of lectures is designed so that there is coordination and integration of theoretical and experimental concepts taught and held in classroom (using the methodology masterful or laboratory) and tutorials (using the platform of e-learning: e-lessons, conducting exercises and analysis of case studies). In the lectures will be made ​​one masterful exposition of the syllabus, and whenever possible, will promote interactive discussion with the students of the materials under study. In laboratory classes discussion and analysis of issues (previously available on the platform) will be privileged and is intended to promote knowledge / interrelationship of classical and emerging mechanisms in pharmacology / pharmacotherapy of various vascular disorders, in which the student should also develop interpersonal skills and personal information such as: communication between students, management skills and teamwork; promotion initiative, leadership and management.

Software

http://moodle.up.pt (plataforma de e-learning)

Evaluation Type

Distributed evaluation with final exam

Assessment Components

designation Weight (%)
Exame 40,00
Participação presencial 30,00
Trabalho escrito 30,00
Total: 100,00

Amount of time allocated to each course unit

designation Time (hours)
Estudo autónomo 0,00
Frequência das aulas 0,00
Trabalho de campo 0,00
Total: 0,00

Calculation formula of final grade

nal rating = 40% final exam 60% distributed evaluation

  Distributed evaluation:

a) contribution of 30% on the discussion and analysis of scientific articles (case studies)

b) contribution of 30% on the design, presentation and defense of a scientific project

  Okay - final grade equal to or greater than 9.50 values​​. Are not provided oral evidence.

Recommend this page Top
Copyright 1996-2024 © Faculdade de Farmácia da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2024-07-16 at 19:23:47 | Acceptable Use Policy | Data Protection Policy | Complaint Portal